223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

https://doi.org/10.1016/j.annonc.2020.10.443Get rights and content
Under an Elsevier user license
open archive

Cited by (0)